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Background: Gastrointestinal stromal tumors are rare soft tissue sarcomas that typically develop from
mesenchymal cells with acquired gain-in-function mutations in KIT or PDGFRA oncogenes. These somatic mutations
have been well-characterized, but little is known about inherited genetic risk factors. Given evidence that certain
susceptibility loci and carcinogens are associated with characteristic mutations in other cancers, we hypothesized
that these signature KIT or PDGFRA mutations may be similarly fundamental to understanding gastrointestinal
stromal tumor etiology. Therefore, we examined associations between 522 single nucleotide polymorphisms and
seven KIT or PDGFRA tumor mutations types. Candidate pathways included dioxin response, toxin metabolism,
matrix metalloproteinase production, and immune and inflammatory response.
Methods: We estimated odds ratios and 95% confidence intervals for associations between each candidate SNP
and tumor mutation type in 279 individuals from a clinical trial of adjuvant imatinib mesylate. We used sequence
kernel association tests to look for pathway-level associations.
Results: One variant, rs1716 on ITGAE, was significantly associated with KIT exon 11 non-codon 557–8 deletions
(odds ratio = 2.86, 95% confidence interval: 1.71-4.78) after adjustment for multiple comparisons. Other noteworthy
associations included rs3024498 (IL10) and rs1050783 (F13A1) with PDGFRA mutations, rs2071888 (TAPBP) with wild
type tumors and several matrix metalloproteinase SNPs with KIT exon 11 codon 557–558 deletions. Several
pathways were strongly associated with somatic mutations in PDGFRA, including defense response (p = 0.005) and
negative regulation of immune response (p = 0.01).
Conclusions: This exploratory analysis offers novel insights into gastrointestinal stromal tumor etiology and
provides a starting point for future studies of genetic and environmental risk factors for the disease.
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GeneticsBackground
Gastrointestinal stromal tumors, or GISTs, are soft tissue
sarcomas that develop from mesenchymal connective tis-
sue anywhere in the gastrointestinal tract, though they
most frequently appear in the stomach or small intestine
[1-3]. Recent advances in molecular biology have revealed
a distinct subset of these tumors that express tyrosine* Correspondence: Larry.Engel@unc.edu
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stated.kinase receptors or platelet-derived growth factor recep-
tors [4-6]. The presence of these receptors, encoded by
the KIT or PDGFRA oncogenes, respectively, is an indi-
cation that these tumors share a common origin of the
interstitial cells of Cajal, the pacemaker cells of the gut.
The Cajal cells normally express both CD117, the immu-
nohistochemical (IHC) marker for tyrosine kinase recep-
tors, and CD34, the IHC marker for platelet-derived
growth factor receptors, and GISTs likely develop fromLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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mutations [4,7,8]. KIT exon 11 (50-60% of cases) and KIT
exon 9 (5-10% of cases) are the most common mutation
sites [2,9,10]. Such mutations can enable receptor activa-
tion in the absence of normal stem cell factor signaling
mechanisms, thereby over-stimulating cell proliferation
and leading to tumor development. Based on this dis-
covery, a 2001 National Institutes of Health consensus
panel [8] agreed to formally define GISTs as mesenchy-
mal neoplasms of the gastrointestinal tract displaying
positivity for CD117 or CD34, with some exceptions
allowed for immunonegative tumors with otherwise
consistent histology.
These relatively new and complex diagnostic cri-
teria make disease surveillance and etiologic study diffi-
cult. In a recent evaluation of patients in the National
Cancer Institute’s Surveillance, Epidemiology and End
Results database, Rubin et al. [11] estimated an annual
age-adjusted incidence rate of 0.32 cases per 100,000
individuals in the United States (US). The rarity of the
disease makes it a difficult subject for population-
based research or for prompt and unbiased assessment
of non-genetic risk factors in any study population.
An evaluation of the genetic determinants of GIST is
much more feasible, as the germline DNA of individ-
uals does not change over time or in response to dis-
ease processes. To date, no other research groups have
published such evaluations.
To help fill this knowledge gap, we investigated the
genetic determinants of GIST in a case-only analysis.
Specifically, we examined the associations between select
single nucleotide polymorphisms (SNPs), which are inher-
ited variations in individuals’ DNA, and the several com-
mon types of acquired KIT and PDGFRA mutations
present in GIST tissue. Certain susceptibility loci have been
linked to characteristic mutations, or mutational “signa-
tures”, in other cancers. These include associations between
GSTM1-null genotype and TP53 transversion mutations
among bladder cancer patients [12], and certain functional
polymorphisms in XPD and G:C→T:A TP53 mutations
among lung cancer patients [13]. Similarly, we hypothesized
that the characteristic somatic mutations in the KIT and
PDGFRA genes in GIST tumors may be mutational sig-
natures that are causally linked to specific mutagens or
susceptibility loci. As such, identifying risk factors for
the individual tumor subtypes may be fundamental to
understanding the disease.
We conducted our evaluation in two phases. The first
phase included genes previously linked to soft tissue
sarcoma or to environmental risk factors for soft tissue
sarcoma, such as dioxins, phenoxyherbicides, insecticides,
and vinyl chloride [14-18], as well as genes previously linked
to mutational signatures in other cancers [12,13,19-21]. We
found that several SNPs were associated with GIST tumorsubtypes, including SNPs on two xenobiotic metabolizing
genes, CYP1B1 and GSTM1, and two DNA repair genes,
RAD23B and ERCC2 [22].
The present report includes results from the second
phase of the study, in which we examined the relation-
ship between these 7 somatic mutation categories
and 522 additional candidate SNPs. These SNPs are
located on genes that play secondary or less well-
understood roles in dioxin response or toxin-metabolizing
pathways, as well as SNPs on PDGFRA and 10 matrix
metalloproteinase (MMP) genes, which are often over-
expressed in GISTs and other soft tissue sarcomas
and may be linked to tumor invasion and metastasis
[23-25]. Based on previous evidence that immune and
inflammation-related genes are associated with osteo-
sarcomas and other gastrointestinal tumors [26-28],
we also selected certain SNPs from the GeneChip® Human
Immune and Inflammation SNP Kit genotyping panel
designed by Affymetrix® [29,30].
Our main objective for these analyses was to identify
genes or gene pathways potentially related to GIST car-
cinogenesis. Therefore, in addition to assessing the effect
of each individual SNP, we also assessed the joint effects
of SNPs in the same functional categories. By conducting
these exploratory analyses with a large and diverse gene
panel, our goal is to identify specific variants, genes, or
functional pathways meriting further investigation.
Methods
Study population
The study population consists of the first 279 individuals
from the American College of Surgeons Oncology Group
(ACOSOG) Z9001 clinical trial who provided blood and
tumor tissue samples for ancillary research and had suf-
ficient tumor tissue for mutation analysis. The Z9001
trial was a multicenter, Phase III, randomized, double-
blind study of adjuvant imatinib (Gleevec™; Novartis
Pharmaceuticals) versus placebo. To be eligible for the
clinical trial, cases had to have a CD117+, resected,
localized, primary GIST of at least 3 cm diagnosed be-
tween July 1, 2002 and April 18, 2007. IHC staining
for CD117 was completed using the Dako antibody
(DakoCytomation, Copenhagen, Denmark). Additional
information on the Z9001 trial is published elsewhere
[31]. Institutional Review Boards at all participating
institutions approved this ancillary study and all of
the included participants consented to the use of their
blood and tissue specimens.
SNP selection
Among the target genes described above, we identified
SNPs within 2000 or 500 base pairs of the 5′ and 3′
ends of the coding regions, respectively, that could affect
gene function and had at least a 10% minor allele
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cluded nonsense, missense and splice site mutations, as
well as SNPs overlapping with microRNA seed regions
or transcription binding sites. If the selected SNPs did
not meet design phase quality control standards (desig-
nability score <1 or final score <0.7), we selected a sur-
rogate SNP in high linkage disequilibrium with the
desired SNP. SNPs related to dioxin response or toxin
metabolism (final n = 68), matrix metalloproteinase (final
n = 24), or on PDGFRA (final n = 4) were selected in this
manner.
We selected the remaining SNPs (final n = 426) from a
pre-existing Affymetrix® panel designed to include poten-
tially functional non-synonymous SNPs from 318 genes
related to immune and inflammatory response. Genes
were selected for inclusion based on their gene ontology
(GO) categorization [33]. GO categories were also used
to separate the genes into functional subgroups (see
Additional file 1: Table S1).Lab assays
DNA for mutation analysis was extracted from snap-
frozen tumor tissue and tested for KIT exon 11 mutations
using polymerase chain reaction (PCR) analysis (Platinum
TaqDNA Polymerase High Fidelity; Life Technologies,
Inc., Gaithersburg, MD). The PCR conditions were as fol-
lows: 1) 94°C for 4 min; 2) 94°C for 30 sec, 3) the relevant
annealing temperature for each primer set for 30 sec,
4) 72°C for 30 sec, (35 cycles); and 5) 72°C for 3 min.
The PCR products were identified by agarose gel electro-
phoresis using a 2% MetaPhor™ agarose gel (BioWhittaker
Applications, Rockland, ME). The PCR products were
purified with the QIAquick™ PCR Purification Kit (Qiagen
Inc., Valencia, CA) before sequencing. The sequencing
reactions for each case were performed from both the
forward and reverse directions. Tumors lacking exon 11
mutations were genotyped for mutations in KIT exons
9, 13, 14 and 17 and PDGFRA exons 12 and 18. A more
detailed description of these assays can be found else-
where [34,35].
An initial 544 candidate SNPs were genotyped
using the GoldenGate genotyping assay (Illumina Inc.,
San Diego, CA). Briefly, allele-specific oligos were hy-
bridized directly to genomic DNA extracted from the
blood samples. The hybridized DNA was extended and
ligated to downstream locus-specific oligos and then
amplified using universal PCR fluorescently labeled
primers and allele-specific primers [30,36]. After the
resulting products were hybridized to their comple-
mentary bead types, the arrays were assessed using the
BeadArray™ Reader.
Twenty-seven participants underwent duplicate geno-
type analysis for quality assurance purposes. Concordancefor duplicate samples was 99.9%. After excluding SNPs
that were mono-allelic (n = 3), had >5% missing data
(n = 3), or showed poor clustering (n = 16) among our
study subjects, we had 522 evaluable SNPs, as listed
above. We retained three SNPs that showed evidence
of possible copy number variation, but designated
them accordingly.Statistical analysis
We conducted descriptive analyses of selected demo-
graphic variables, tumor characteristics and genotypes.
As this population includes some non-white partici-
pants, we calculated race-specific MAFs and compared
genotype distributions across racial groups (white vs.
other) using a Pearson χ2 test of association. Fisher’s
exact test was used if one or more cells had less than
5 observations.
We categorized each individual’s tumor based on the
presence or absence of each of the following outcomes:
i) a deletion of KIT exon 11 codons 557–558, ii) any
other (i.e. non-codon 557–8) deletion in KIT exon 11,
iii) a KIT exon 11 insertion, iv) a KIT exon 11 point mu-
tation, v) a KIT exon 9, exon 13, exon 14, or exon 17
mutation, vi) a PDGFRA exon 12 or 18 mutation, and
vii) no KIT or PDGFRA mutation (wild type). KIT muta-
tions in exons 9, 13, 14 and 17 were too rare for inde-
pendent evaluation.
We obtained odds ratios (ORs), 95% confidence inter-
vals (CIs) and p-values for each SNP-mutation combin-
ation using logistic regression. All models were adjusted
for race, sex, and age at diagnosis. We assumed additive
genetic models, denoting whether an individual had 0, 1
or 2 copies of the minor allele. P-values were calculated
using trend tests and were corrected for multiple testing
by controlling for a false discovery rate of 25%. This
method is less conservative than a Bonferroni approach
and is thus better suited for a hypothesis-generating study
such as this [37].
We used a sequence kernel association test (SKAT) to
assess the joint effect of a group of SNPs on an outcome
[38,39]. We grouped SNPs according to their functional
category, as described above. This method is well-powered
to detect associations when SNPs in a group are
correlated with one another but only moderately as-
sociated with the outcome. Briefly, for individual i,
the log odds of having the outcome given genotypes
zi1 to zip and covariates xi1 to xim is modeled semi-
parametrically using a logistic kernel-machine regres-
sion model:
logit P yi ¼ 1ð Þ ¼ α0 þ α1xi1 þ⋯þ αmxim
þ h zi1; zi2;…; zip
 
;
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nel function, K(•,•) and some γi, …, γn:
h Zið Þ ¼
Xn
i¼1
γi 0K Zi;Zi 0ð Þ
We used an identity-by-state kernel: K Zi;Zi0ð Þ ¼
Xp
j¼1
2‐ Zij‐Zi 0 j
   , as this does not require linearity as-
sumptions and allows for epistasis [39]. Assuming h fol-
lows an arbitrary distribution with a mean of 0 and
variance τK, testing the null hypothesis H0: h(Z) = 0 is
equivalent to testing H0: τ=0. This is accomplished using a
modified variance-component score statistic:





p^0i ¼ a^0 þ a^1xi1 þ a^2xi2 þ⋯þ a^mxim:
Here, Q is comparable to a χ2 distribution with scale
parameter κ and ν degrees of freedom, both of which
are modified to account for correlation between SNPs
in the same SNP-set (for calculations, see Appendix A
in Wu et al. [38]).
Results
Males and females were approximately equally repre-
sented in our study population, while 18% were non-
white (Table 1). Median age at diagnosis was 58 years
(range 18–85), though non-white participants tended to
be younger (median age = 53 years). Non-white partici-
pants were also more likely to have a smaller tumor than
white participants (median tumor sizes of 6.0 cm versus
6.5 cm), and more likely to have stomach tumors (74%
versus 64%). Most patients had mutations in KIT exon
11 (70% overall), the largest proportion of which were
codon 557–558 deletions (34% of exon 11 mutations).
Demographic and tumor characteristics were very simi-
lar for males and females.
Compared with the larger ACOSOG Z9001 cohort,
whites were somewhat over-represented in this ancillary
study, which had otherwise similar characteristics (data
not shown). Race-stratified MAF and association p-values
for all 522 SNPs are displayed in Additional file 1:
Table S2. As expected based on genotype distributions
in ethnically diverse HapMap populations [32], geno-
type distributions in this study differed by race for
many of the candidate polymorphisms.
The top 5 SNPs for each mutation subtype are dis-
played in Table 2. Only one SNP, rs1716 on ITGAE,
was statistically significant after adjusting for multiple
comparisons. This SNP was associated with KIT exon11 non-codon 557–8 deletions (OR = 2.86, 95% CI:
1.71, 4.78; p = 6.4×10-5).
Though not statistically significant after adjusting for
multiple comparisons, rs3024498 (IL10) and rs1050783
(F13A1) were strongly associated with PDGFRA muta-
tions (OR = 0.31, 95% CI: 0.16,0.60 and OR= 0.31, 95% CI:
0.16,0.61, respectively) and rs2071888 (TAPBP) was strongly
associated with wild type tumors (OR= 0.37, 95% CI: 0.20,
0.67). Additionally, several SNPs in matrix metallopro-
teinase genes were associated with tumor subtypes.
MMP10 and MMP1 SNPs were associated with KIT
exon 11 codon 557–558 deletions, 2 MMP7 SNPs were
associated with KIT exon 11 point mutations and a
MMP1 SNP was associated with KIT exon 9, 13, 14, or
17 mutations. Effect estimates and p-values for all 522
SNPs can be found in Additional file 1: Table S3. The
relative magnitude of all SNP-subtype associations is
depicted in Figure 1.
Despite strong SNP-level effects, the MMP pathway
was not associated with any of the tumor subtypes in
the SKAT analyses (minimum p-value =0.2 for KIT exon
11 point mutations; Additional file 1: Table S4). As seen
in Table 3, the strongest pathway-level associations
were in relation to somatic mutations in PDGFRA. This
included defense response (p = 0.005), negative regula-
tion of immune response (p = 0.01), protein phosphoryl-
ation (p = 0.02), positive regulation of immune response
(p = 0.03), and AHR/dioxin response (0.03). Additionally,
negative regulation of cell proliferation was associated
with PDGFRA mutations (p = 0.04; Additional file 1:
Table S4). In total, only 5 other pathways were associated
with a tumor subtype at p < 0.05. These were AHR/dioxin
response with non exon 11 KIT mutations (p = 0.01),
humoral immune response with wild type mutations
(p = 0.02), and response to stress, negative regulation
of apoptosis, and protein tyrosine kinase activity with
non-codon 557–8 KIT exon 11 deletions (p = 0.02, p = 0.03,
and p = 0.04, respectively). No pathways were statisti-
cally significant after correcting for multiple testing.
Log p-values for all pathway analyses can be seen in
Figure 2.
Discussion
In this exploratory analysis of genetic risk factors for
GIST tumor subtypes, we identified one statistically sig-
nificant association and a number of other potentially
important associations for individual polymorphisms. We
also identified several potentially relevant functional path-
ways. These novel findings offer clues about the etiology
of these rare and poorly understood tumors.
The SNP with the strongest association with a tumor
subtype was rs1716 on ITGAE. This SNP results in a
missense mutation on ITGAE (also known as CD103), a
gene involved in protein tyrosine phosphatase activity.
Table 1 Demographic information and tumor characteristics of patients included in genotyping ancillary study
Overall sample Sex stratified Race stratified








Age: Median (range) 58.0 (18 – 85) 57.0 (18 – 85) 58.0 (18 – 81) 59.0 (18 – 85) 53.0 (27 – 78)
Sex: N (%)
Male 142 (51) — — — —
Female 137 (49) — — — —
Race: N (%)
White 229 (82) 122 (86) 107 (78) — —
Other 50 (18) 20 (14) 30 (22) — —
Tumor Size: Median (range) 6.5 (3.0 – 37.0) 6.0 (3.0 – 37.0) 6.5 (3.0 – 28.0) 6.5 (3.0 – 37.0) 6.0 (3.1 – 30.0)
Tumor Size: N(%)
<5 cm 79 (28) 41 (29) 38 (28) 65 (28) 14 (28)
5-10 cm 146 (52) 72 (51) 74 (54) 119 (52) 27 (54)
>10 cm 54 (19) 29 (20) 25 (18) 45 (20) 9 (18)
Mitotic Rate: Median (range) 3 (0 – 351) 3 (0 – 351) 3 (0 – 207) 3 (0 – 351) 4.5 (0 – 81)
Mitotic Rate: N(%)
<5 156 (60) 77 (58) 79 (63) 132 (62) 24 (50)
≥5 104 (40) 57 (42) 47 (37) 80 (38) 24 (50)
Missing 19 8 11 17 2
Tumor Location: N(%)
Stomach 182 (66) 97 (69) 85 (63) 146 (64) 36 (74)
Small Intestine 85 (31) 39 (28) 46 (34) 77 (34) 8 (16)
Rectum 2 (1) 1 (1) 1 (1) 1 (0) 1 (2)
Other 8 (3) 4 (3) 4 (3) 4 (2) 4 (8)
Missing 2 1 1 1 1
Mutation Type: N(%)
Exon 9 15 (5) 9 (6) 6 (4) 15 (7) 0 (0)
Exon 11 195 (70) 95 (67) 100 (73) 153 (67) 42 (84)
Exon 13 3 (1) 0 (0) 3 (2) 2 (1) 1 (2)
Exon 14 1 (0) 1 (1) 0 (0) 1 (0) 0 (0)
Exon 17 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
PDGFRA 29 (10) 21 (15) 8 (6) 25 (11) 4 (8)
Wild type 36 (13) 16 (11) 20 (15) 33 (14) 3 (6)
Exon 11 mutation type: N(%)
557-558 deletion 66 (34) 33 (35) 33 (33) 51 (33) 15 (36)
Other deletion 45 (23) 25 (26) 20 (20) 34 (22) 11 (26)
Insertion 28 (14) 14 (15) 14 (14) 23 (15) 5 (12)
Point Mutation 56 (29) 23 (24) 33 (33) 45 (29) 11 (26)
PDGFRA mutation type: N(%)
D842V 12 (41) 10 (48) 2 (25) 10 (40) 2 (50)
Other 17 (59) 11 (52) 6 (75) 15 (60) 2 (50)
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Table 2 Odds ratios (ORs) for top 5 SNP-mutation associations, by mutation type
KIT exon 11 codon 557–558 deletion
Gene MMP10 MMP1 MMP10 SELP GRN
SNP rs3819099 rs17293642 rs17293348 rs6131 rs5848
MAFa 0.11/0.20 0.11/0.20 0.12/0.20 0.18/0.30 0.31/0.45
OR (95% CI) 2.29 (1.30, 4.01) 2.17 (1.25, 3.77) 2.16 (1.24, 3.77) 1.81 (1.18, 2.78) 1.78 (1.17, 2.73)
p-value 0.004 0.006 0.007 0.007 0.007
KIT exon 11 other (non-codon 557–8) deletion
Gene ITGAE CDK2 FCER1G ZAP70 LIF
SNP rs1716 rs2069398 rs11421 rs2276645 rs737812
MAFa 0.25/0.45 0.07/0.19 0.15/0.27 0.40/0.22 0.35/0.20
OR (95% CI) 2.86 (1.71, 4.78) 2.62 (1.34, 5.13) 2.13 (1.24, 3.64) 0.49 (0.28, 0.83) 0.47 (0.26, 0.83)
p-value 0.00006 0.005 0.006 0.008 0.01
KIT exon 11 insertion
Gene SH2B3 CLCF1 GZMB IFI16 GMIP
SNP rs3184504 rs17608 rs8192917 rs866484 rs880090
MAFa 0.43/0.23 0.32/0.48 0.24/0.41 0.26/0.44 0.32/0.48
OR (95% CI) 0.31 (0.15, 0.64) 2.55 (1.38, 4.72) 2.33 (1.28, 4.24) 2.36 (1.27, 4.40) 2.20 (1.23, 3.94)
p-value 0.002 0.003 0.006 0.007 0.008
KIT exon 11 point mutation
Gene MMP7 PTGER3 PTPN12 MMP7 SLAMF1
SNP rs10502001 rs959 rs3750050 rs14983 rs2295612
MAFa 0.18/0.29 0.18/0.31 0.16/0.29 0.19/0.29 0.17/0.07
OR (95% CI) 2.20 (1.32, 3.66) 1.99 (1.25, 3.17) 2.01 (1.25, 3.25) 2.03 (1.22, 3.39) 0.33 (0.15, 0.74)
p-value 0.003 0.004 0.004 0.006 0.007
Other KIT mutation
Gene LILRA4 LAG3 IL4R MMP1 ITGAE
SNP rs2241384 rs870849 rs1805015 rs4754880 rs1716
MAFa 0.17/0.36 0.36/0.42 0.18/0.36 0.18/0.36 0.27/0.50
OR (95% CI) 2.89 (1.36, 6.16) 2.76 (1.33, 5.74) 2.75 (1.32, 5.75) 2.49 (1.22, 5.09) 2.46 (1.22, 4.99)
p-value 0.006 0.007 0.007 0.01 0.01
PDGFRA mutation
Gene IL10 F13A1 PLAU PECAM1 SPINK5
SNP rs3024498 rs1050783 rs4065 rs1050382 rs6892205
MAFa 0.21/0.41 0.14/0.33 0.46/0.24 0.47/0.31 0.49/0.31
OR (95% CI) 0.31 (0.16, 0.60) 0.31 (0.16, 0.61) 2.65 (1.37, 5.13) 0.43 (0.24, 0.78) 2.31 (1.26, 4.24)
p-value 0.0004 0.0007 0.004 0.006 0.007
Wild type
Gene TAPBP ESR1 NCF2 STAT2 FGA
SNP rs2071888 rs6557171 rs2274064 rs2066807 rs6050
MAFa 0.48/0.29 0.38/0.46 0.43/0.38 0.06 /0.15 0.26/0.39
OR (95% CI) 0.37 (0.20, 0.67) 2.26 (1.35, 3.79) 2.35 (1.34, 4.13) 3.00 (1.32, 6.83) 2.02 (1.19, 3.44)
p-value 0.001 0.002 0.003 0.009 0.009
aMinor allele frequency (MAF) among those without mutation / MAF among those with mutation.
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of melanoma [40], as was another SNP in the gene. The
CD103 protein is commonly expressed in intraepithelial
lymphocytic T cells and hairy cell leukemia cells [41,42].
The IL10 SNP associated with PDGFRA mutations,
rs3024498, is located in a seed microRNA region. One
previous study found an association between rs3024498
and colorectal cancer [43]. The IL10 gene encodes a
cytokine that plays a role in immunoregulation and in-
flammation, and has been previously linked to severalcancers, including osteosarcoma [26], cervical cancer
[44], and gastric cancer [45,46].
rs1050783 in F13A1 is also in a seed microRNA re-
gion, but neither the SNP nor the gene has been previ-
ously linked to cancer. The same is true for rs2071888
in TAPBP, a missense mutation. As noted above, several
studies have observed over-expression of matrix metallo-
proteinase genes in GISTs and other soft tissue sarcomas
[23-25], though none of the evaluated SNPs have previ-
ously been associated with cancer risk.
Figure 1 Log p-values for the association between each candidate SNP and tumor mutation type.
Table 3 SKAT p-values for top 5 functional pathway- mutation associations, by mutation type
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Figure 2 SKAT log p-values for the association between each functional pathway and tumor mutation type.
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but there is little consistency in how the pathways are
defined. We selected the well-documented and publicly
available Gene Ontology [33] classification system to fa-
cilitate replication and follow-up studies. Although we
did not identify any studies that examined the specific
pathways included in the present analyses, numerous
studies have observed associations of inflammatory or
immune response genes with risk of sarcomas or gastro-
intestinal cancers [26,28,30,47].
The present exploratory study was undertaken in light
of evidence suggesting that some mutagens and suscepti-
bility loci are associated with specific mutational “signa-
tures,” i.e., characteristic mutation patterns [12,13,19-21].
At this point, GIST etiology has been insufficiently
researched, and we do not know how well the mutation-
based tumor classifications used in this study correspond
to distinct carcinogenic processes. However, the existence
of multiple types of mutations suggest that more than
one mutagenic process could be involved, and we be-
lieve that identifying associations between germline gen-
etic polymorphisms and unique tumor phenotypes could
contribute valuable new information about disease eti-
ology. This information could also help to elucidate
environmental risk factors for this disease.
Because tumors with KIT exon 11 mutations were not
assessed for other KIT or PDGFRA mutations, some
tumors may be misclassified, though evidence from
population-based studies suggests that few GISTs have
more than one mutation type [2,9]. Our study participantshad similar mutation profiles to the individuals included
in these population-based investigations, but the results
from this predominately white clinical trials population
may not be generalizable to all GIST patients. Lastly, this
study had a small sample size. As such, we had limited
power to detect true associations, particularly when the
evaluated genotype and mutation type were rare.
Conclusions
In this novel study of genetic risk factors for GIST, we
identified several SNPs and gene pathways associated
with GIST mutation subtypes. This included SNPs in-
volved in dioxin response, toxin metabolism, matrix
metalloproteinase synthesis, and inflammatory or im-
mune response. While only a single SNP was statistically
significant after correcting for multiple comparisons, our
overall findings provide an important starting point for
future studies of genetic and environmental risk factors
for this rare and poorly understood disease.Additional file
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